Pipeline

Drugging the “Undruggable”

Canonical disease drivers, but have not been drugged

Improved Drugs for Validated Targets

Improved selectivity or drug characteristics vs available therapeutics

Genetic
Diseases

Well-understood biology

Novel
Targets

Leverage the power and scale of academic collaborations to explore novel biology

Our Pipeline

Each disease area and drug program in our pipeline takes us one step closer to transforming preclinical R&D using computational chemistry to discover small molecule drugs more efficiently than traditional approaches to deliver better medicines, faster.

Wholly Owned

Contact us to learn more about out-licensing our assets.

Disease Area
Target
Discovery
Optimization
Preclinical
logo x37
Immunology
TYK2
Immunology
RIPK1
Immunology
RIPK2
15 Undisclosed
undisclosed
18 Undisclosed
undisclosed

Co-Developed

Learn more about our growing portfolio companies.

Co-Development
Partner
Disease Area
Target
Discovery
Optimization
Preclinical
logo x37
Oncology
PIM3
Oncology
SHP2
Hematology
Factor XII
Immunology
cGAS

Academic Collaborations

Learn more about our research partnerships and biopharma partnerships.

Disease Areas

Learn more about our portfolio, pipeline, and career opportunities.

Contact Us